CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 118 enrolled
Drug / intervention
Triptorelin pamoate +1 moredrug
Likely dose
Triptorelin pamoate 22.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01161563
NCT01161563Phase 4Completed
CompareCT.gov

Randomized Crossover Trial to Assess the Tolerability of GnRH Analogue Administration in Patients With Advanced Prostate Cancer

Watson Pharmaceuticals·interventional·Posted Jul 13, 2010·Updated Sep 6, 2013

In Brief

A Phase 4 clinical trial evaluating Triptorelin pamoate and Leuprolide acetate for Prostate Cancer. Completed, enrolled 118 participants across 16 sites.

Detailed Summary

The purpose of this study is to compare how subjects feel after receiving injections of two different types of GnRH six months apart. One injection is given under the skin of the abdomen, and the other one into the muscle of the buttock or thigh.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 13, 2010
Enrollment StartJul 1, 2010
Primary CompletionApr 1, 2011
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 16.0 years ago

Interventions

Triptorelin pamoatedrug

Triptorelin pamoate for injectable suspension 22.5 mg administered as a single intramuscular injection in either buttock

Leuprolide acetatedrug

Leuprolide acetate for injectable suspension 45 mg administered as a single subcutaneous injection in the upper- or mid-abdominal area.